Patients were followed for clinical toxicities, alterations in model for end-stage-lier disease (MELD) score, tumor response, downstaging to RFA, resection, transplantation, and surial.
英
美
- 随访观察患者的临床毒性,晚期肝脏疾病模型(MELD)评分变化,肿瘤反应,争取降期可射频消融(RFA),切除,肝移植和存活率。